Telehealth Reviews

How GLP-1 Telehealth Actually Works: From Intake to First Dose (and the Red Flags at Each Step)

By the US Health Digest editorial team · Updated July 21, 2026

Every GLP-1 telehealth program follows the same six-step pipeline — online intake, clinician review, a prescription decision, pharmacy fulfilment, dose escalation over months, and ongoing check-ins — and at each step there is a legitimate version and a corner-cutting version. With KFF polling finding that about 1 in 8 US adults has used a GLP-1 medication, and the FDA having warned 30 telehealth companies in March 2026 over illegal marketing of compounded GLP-1s, knowing what each step should look like is the most practical fraud filter you have.

This guide describes the process structurally — what happens, in what order, and what a real medical service does differently from a subscription funnel wearing a lab coat. For which specific programs pass these tests, see our 2026 comparison of GLP-1 telehealth programs for women.

Step 1: The online intake questionnaire

Legitimate version: A detailed medical history that takes real effort to complete. Expect questions about your current medications, past surgeries, thyroid history (personal or family history of medullary thyroid carcinoma), pancreatitis, gallbladder disease, eating-disorder history, mental health, and — critically for women — whether you are pregnant, breastfeeding, or planning pregnancy. GLP-1 medications are not used in pregnancy, so a service that never asks is not screening you; it is processing you.

Red-flag version: A quiz that is really a marketing survey — height, weight, goal weight, credit card. If the questionnaire could not possibly disqualify anyone, it exists to qualify your payment, not your health. The FTC's guide to false weight-loss claims is a useful companion here: services that skip screening tend to also make the promises that guide flags.

Step 2: Clinician review — synchronous or asynchronous

Legitimate version: A licensed clinician, licensed in your state, actually reviews your intake. Some programs do this by live video ("synchronous"); others review asynchronously and message you questions. Asynchronous care is not inherently a red flag — but you should be able to see the clinician's name and credentials, and they should come back with at least one question or confirmation if anything in your history is ambiguous.

Red-flag version: No identifiable clinician, no state-licensure information, and no way to ask a human anything before the prescription appears. If you cannot find out who is prescribing to you, treat that as disqualifying.

Step 3: The prescription decision

Legitimate version: A genuine yes-or-no decision. Real programs decline people — because of contraindications, because of pregnancy plans, because a BMI or history doesn't support treatment. You should also be told exactly which medication you are getting: an FDA-approved branded product, or a compounded version, which the FDA has raised specific safety concerns about. Our compounded vs branded explainer covers that distinction in full.

Red-flag version: "Prescription in 5 minutes" as a selling point. Speed marketed as the product is a rubber stamp, not a medical judgment — a decision made before your answers were read. Vagueness about whether the drug is compounded is the second tell; it was central to the FDA's warning letters to 30 telehealth companies.

Step 4: Pharmacy fulfilment and shipping

Legitimate version: The prescription goes to a named, licensed US pharmacy. Injectable GLP-1 medications are temperature-sensitive, so legitimate services ship in cold packaging, tell you how to check the medication arrived in good condition, and tell you how to store it. You receive proper labeling, dosing instructions, and needle-disposal guidance.

Red-flag version: No named pharmacy, vials with minimal labeling, no storage or cold-chain information, or product shipped from outside the US pharmacy system. Unlabeled or vaguely sourced injectables sit squarely inside the FDA's stated concerns about unapproved GLP-1 products, which include dosing errors and uncertain ingredients.

Step 5: Dose escalation over the following months

Legitimate version: GLP-1 treatment starts at a low dose and steps up gradually over months — the schedule used in the clinical trials we summarize in our review of semaglutide trial results in women. A real program manages this: it tells you the schedule in advance, adjusts it if side effects like nausea are hitting hard, and gives you a named contact for dose questions between shipments.

Red-flag version: Auto-shipping ever-higher doses on a fixed calendar with nobody to talk to. Dose escalation without dose management is a subscription pretending to be titration — and it is exactly when side effects most need clinical eyes.

Step 6: Ongoing check-ins and renewals

Legitimate version: Periodic clinician check-ins before renewals — weight, side effects, any new medications or pregnancy plans — plus clear, findable cancellation. You should be able to pause or stop billing without calling a retention line, and stopping medication should come with guidance, not silence.

Red-flag version: Renewals that are purely a billing event, and auto-billing you cannot opt out of online. If cancelling is harder than subscribing, the company has told you what business it is really in.

The six steps at a glance

A program can pass five steps and fail one — and the failed step tells you where it cuts corners under pressure. If you are still weighing whether telehealth is the right route at all, our GLP-1 FAQ for women covers eligibility, side effects, and the questions to bring to any prescriber, telehealth or in person.